Pharmacokinetic properties of hemoglobin vesicles as a substitute for red blood cells

Drug Metabolism Reviews

Volumn 43, Issue 3, 2011, Pages 362-373

  Taguchi, Kazuaki ^a   Maruyama, Toru ^a   Otagiri, Masaki ^a,b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b SOJO UNIVERSITY   (Japan)

Author keywords

Accelerated blood clearance phenomenon; Artificial oxygen carrier; Disposition; Hemorrhagic shock; Hepatic chronic cirrhosis; Liposome; Mononuclear phagocyte system

Indexed keywords

ARTIFICIAL OXYGEN CARRIER; BLOOD SUBSTITUTE; FLUOROCARBON; HEMOGLOBIN; HEMOGLOBIN BASED OXYGEN CARRIER; MACROGOL; METHEMOGLOBIN; OXYGEN; PERFLUOROCARBON BASED OXYGEN CARRIER; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CHRONIC LIVER FAILURE; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; ERYTHROCYTE; HEMOGLOBIN VESICLE; HEMORRHAGIC SHOCK; HUMAN; NONHUMAN; ONCOTIC PRESSURE; PARTICLE SIZE; PHAGOCYTE; PHOSPHOLIPID VESICLE; PHYSICAL CHEMISTRY; REVIEW;

ANIMALS; BLOOD SUBSTITUTES; END STAGE LIVER DISEASE; ERYTHROCYTES; FLUOROCARBONS; HEMOGLOBINS; HUMANS; OXYGEN; SHOCK, HEMORRHAGIC; TRANSPORT VESICLES;

EID: 79960738078     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2011.558094     Document Type: Review

References (67)

1. Abe, H., Ikebuchi, K., Hirayama, J., Fujihara, M., Takeoka, S., Sakai, H., et al. (2001). Virus inactivation in hemoglobin solution by heat treatment. Artif Cells Blood Substit Immobil Biotechnol 29:381-388. (Pubitemid 33029531)
2. Abernethy, D. R., Greenblatt, D. J., Divoll, M., Harmatz, J. S., Shader, R. I. (1981). Alterations in drug distribution and clearance due to obesity. J Pharmacol Exp Ter 217:681-685. (Pubitemid 11082253)
3. Awasthi, V., Yee, S. H., Jerabek, P., Goins, B., Phillips, W. T. (2007). Cerebral oxygen delivery by liposome-encapsulated hemoglobin: a positron-emission tomographic evaluation in a rat model of hemorrhagic shock. J Appl Physiol 103:28-38. (Pubitemid 47092274)
4. Balla, J., Vercellotti, G. M., Jeney, V., Yachie, A., Varga, Z., et al. (2005). Heme, heme oxygenase, and ferritin in vascular endothelial cell injury. Mol Nutr Food Res 49:1030-1043. (Pubitemid 41735563)
5. Bekersky, I., Fielding, R. M., Dressler, D. E., Kline, S., Buell, D. N., Walsh, T. J. (2001). Pharmacokinetics, excretion, and mass balance of 14C after administration of 14C-cholesterol-labeled AmBisome to healthy volunteers. J Clin Pharmacol 41:963-971. (Pubitemid 32786570)
6. Burhop, K., Gordon, D., Estep, T. (2004). Review of hemoglobin-induced myocardial lesions. Artif Cells Blood Substit Immobil Biotechnol 32:353-374. (Pubitemid 39362756)
7. Chang, T. M., Powanda, D., Yu, W. P. (2003). Analysis of polyethylene-glycol-polylactide nano-dimension artifcial red blood cells in maintaining systemic hemoglobin levels and prevention of methemoglobin formation. Artif Cells Blood Substit Immobil Biotechnol 31:231-247. (Pubitemid 36917864)
8. Chen, J. Y., Scerbo, M., Kramer, G. (2009). A review of blood substitutes: examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers. Clinics (Sao Paulo) 64:803-813.
9. Creteur, J., Vincent, J. L. (2003) Hemoglobin solutions. Crit Care Med 31:S698-S707 (Pubitemid 38010657)
10. Dams, E. T., Laverman, P., Oyen, W. J., Storm, G., Scherphof, G. L., van Der Meer, J. W., et al. (2000). Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ter 292:1071-1079. (Pubitemid 30136603)
11. Gabizon, A., Shmeeda, H., Barenholz, Y. (2003). Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419-436. (Pubitemid 36649037)
12. Goins, B., Klipper, R., Sanders, J., Clif, R. O., Rudolph, A. S., Phillips, W. T. (1995). Physiological responses, organ distribution, and circulation kinetics in anesthetized rats after hypovolemic exchange transfusion with technetium-99m-labeled liposome-encapsulated hemoglobin. Shock 4:121-130.
13. Grone, E. F. , Grone, H. J. (2008). Does hyperlipidemia injure the kidney? Nat Clin Pract Nephrol 4:424-425.
14. Hughes, G. S., Jr., Francome, S. F. , Antal, E. J., Adams, W. J., Locker, P. K., Yancey, E. P., et al. (1995). Hematologic efects of a novel hemoglobin-based oxygen carrier in normal male and female subjects. J Lab Clin Med 126:444-451.
15. Ishida, T., Ichihara, M., Wang, X., Kiwada, H. (2006a). Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J Contr Rel 115:243-250. (Pubitemid 44634842)
16. Ishida, T., Ichihara, M., Wang, X., Yamamoto, K., Kimura, J., Majima, E., et al. (2006b). Injection of PEGylated liposomes in rats elicits PEG-specifc IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Contr Rel 112:15-25.
17. Ishida, T., Kashima, S., Kiwada, H. (2008). Te contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats. J Contr Rel 126:162-165.
18. Ishida, T., Maeda, R., Ichihara, M., Irimura, K., Kiwada, H. (2003a). Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Contr Rel 88:35-42. (Pubitemid 36173950)
19. Ishida, T., Masuda, K., Ichikawa, T., Ichihara, M., Irimura, K., Kiwada, H. (2003b). Accelerated clearance of a second injection of PEGylated liposomes in mice. Int J Pharm 255:167-174. (Pubitemid 36369600)
20. Izumi, T., Enomoto, S., Hosiyama, K., Sasahara, K., Shibukawa, A., Nakagawa, T., et al. (1996). Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ter 277:1630-1641. (Pubitemid 27167181)
21. Jahr, J. S., Moallempour, M., Lim, J. C. (2008). HBOC-201, hemoglobin glutamer-250 (bovine), Hemopure (Biopure Corporation). Exp Opin Biol Ter 8:1425-1433.
22. Jahr, J. S., Walker, V. , Manoochehri, K. (2007). Blood substitutes as pharmacotherapies in clinical practice. Curr Opin Anaesthesiol 20:325-330. (Pubitemid 47051893)
23. Kadowaki, D., Anraku, M., Tasaki, Y., Kitamura, K., Wakamatsu, S., Tomita, K., et al. (2007). Efect of olmesartan on oxidative stress in hemodialysis patients. Hypertens Res 30:395-402. (Pubitemid 46958889)
24. Kiwada, H., Matsuo, H., Harashima, H. (1998). Identifcation of proteins mediating clearance of liposomes using a liver perfusion system. Adv Drug Deliv Rev 32:61-79. (Pubitemid 28277176)
25. Kristiansen, M., Graversen, J. H., Jacobsen, C., Sonne, O., Hofman, H. J., Law, S. K., et al. (2001). Identifcation of the haemoglobin scavenger receptor. Nature 409:198-201.
26. Kuipers, F., Spanjer, H. H., Havinga, R., Scherphof, G. L., Vonk, R. J. (1986). Lipoproteins and liposomes as in vivo cholesterol vehicles in the rat: preferential use of cholesterol carried by small unilamellar liposomes for the formation of muricholic acids. Biochim Biophys Acta 876:559-566.
27. Lee, J., Yoon, S., Nho, K. (2006). Pharmacokinetics of 125I-radiolabelled PEG-hemoglobin SB1. Artif Cells Blood Substit Immobil Biotechnol 34:277-292.
28. Lok, C. (2001). Blood product from cattle wins approval for use in humans. Nature 410:855. (Pubitemid 32335805)
29. Natanson, C., Kern, S. J., Lurie, P., Banks, S. M., Wolfe, S. M. (2008). Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 299:2304-2312. (Pubitemid 351724397)
30. Noble, C. O., Krauze, M. T., Drummond, D. C., Yamashita, Y., Saito, R., Berger, M. S., et al. (2006). Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efcacy. Cancer Res 66:2801-2806.
31. Nose, Y. (2004). Is there a role for blood substitutes in civilian medicine: a drug for emergency shock cases? Artif Org 28:807-812. (Pubitemid 39159153)
32. Okamura, Y, Takeoka, S, Eto, K, Maekawa, I, Fujie, T, Maruyama, H, et al. (2009). Development of fbrinogen gamma-chain peptide-coated, adenosine diphosphate-encapsulated liposomes as a synthetic platelet substitute. J Tromb Haemost 7:470-477.
33. Okumura, H., Katoh, M., Minami, K., Nakajima, M., Yokoi, T. (2007). Change of drug excretory pathway by CCl4-induced liver dysfunction in rat. Biochem Pharmacol 74:488-495. (Pubitemid 46963235)
34. Pape, A., Habler, O. (2007). Alternatives to allogeneic blood transfusions. Best Pract Res Clin Anaesthesiol 21:221-239. (Pubitemid 46888189)
35. Parry, E. (1988). Blood substitutes: historical perspective. In: Lowe, K. C. (Ed.), Blood substitute: preparation, phisiology, and medical applications (pp. 17-49). New York: Ellis Horwood.
36. Plock, J. A., Rafatmehr, N., Sinovcic, D., Schnider, J., Sakai, H., Tsuchida, E., et al. (2009). Hemoglobin vesicles improve wound healing and tissue survival in critically ischemic skin in mice. Am J Physiol Heart Circ Physiol 297:H905-H910
37. Sakai, H., Horinouchi, H., Tomiyama, K., Ikeda, E., Takeoka, S., Kobayashi, K., et al. (2001) Hemoglobin-vesicles as oxygen carriers: infuence on phagocytic activity and histopathological changes in reticuloendothelial system. Am J Pathol 159:1079-1088. (Pubitemid 32847198)
38. Sakai, H., Masada, Y., Horinouchi, H., Ikeda, E., Sou, K., Takeoka, S., et al. (2004a). Physiological capacity of the reticuloendothelial system for the degradation of hemoglobin vesicles (artifcial oxygen carriers) after massive intravenous doses by daily repeated infusions for 14 days. J Pharmacol Exp Ter 311:874-884. (Pubitemid 39612691)
39. Sakai, H., Masada, Y., Horinouchi, H., Yamamoto, M., Ikeda, E., Takeoka, S., et al. (2004b). Hemoglobin-vesicles suspended in recombinant human serum albumin for resuscitation from hemorrhagic shock in anesthetized rats. Crit Care Med 32:539-545. (Pubitemid 38234138)
40. Sakai, H., Seishi, Y., Obata, Y., Takeoka, S., Horinouichi, H., Tsuchida, E., et al. (2009). Fluid resuscitation with artifcial oxygen carriers in hemorrhaged rats: profles of hemoglobin-vesicle degradation and hematopoiesis for 14 days. Shock 31:192-200.
41. Sakai, H., Sou, K., Horinouchi, H., Kobayashi, K., Tsuchida, E. (2008). Haemoglobin-vesicles as artifcial oxygen carriers: present situation and future visions. J Intern Med 263:4-15. (Pubitemid 350243556)
42. Sakai, H., Takeoka, S., Yokohama, H., Seino, Y., Nishide, H., Tsuchida, E. (1993). Purifcation of concentrated hemoglobin using organic solvent and heat treatment. Prot Expr Purif 4:563-569. (Pubitemid 2007179)
43. Sakai, H., Tomiyama, K. I., Sou, K., Takeoka, S., Tsuchida, E. (2000). Poly(ethylene glycol)-conjugation and deoxygenation enable long-term preservation of hemoglobin-vesicles as oxygen carriers in a liquid state. Bioconjug Chem 11:425-432. (Pubitemid 30324910)
44. Sakai, H., Tsuchida, E. (2007). Hemoglobin-vesicles for a transfusion alternative and targeted oxygen delivery. J Liposome Res 17:227-235. (Pubitemid 350133590)
45. Savitsky, J. P., Doczi, J., Black, J., Arnold, J. D. (1978). A clinical safety trial of stroma-free hemoglobin. Clin Pharmacol Ter 23:73-80. (Pubitemid 8290413)
46. Sehgal, L. R., Gould, S. A., Rosen, A. L., Sehgal, H. L., Moss, G. S. (1984). Polymerized pyridoxylated hemoglobin: a red cell substitute with normal oxygen capacity. Surgery 95:433-438. (Pubitemid 14133924)
47. Shimoishi, K., Anraku, M., Kitamura, K., Tasaki, Y., Taguchi, K., Hashimoto, M., et al. (2007). An oral adsorbent, AST-120, protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure. Pharm Res 24:1283-1289. (Pubitemid 46870593)
48. Smani, Y. (2008). Hemospan: a hemoglobin-based oxygen carrier for potential use as a blood substitute and for the potential treatment of critical limb ischemia. Curr Opin Investig Drugs 9:1009-1019.
49. Sou, K., Endo, T., Takeoka, S., Tsuchida, E. (2000). Poly(ethylene glycol)-modifcation of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles. Bioconjug Chem 11:372-379. (Pubitemid 30324903)
50. Sou, K., Goins, B., Takeoka, S., Tsuchida, E., Phillips, W. T. (2007). Selective uptake of surface-modifed phospholipid vesicles by bone marrow macrophages in vivo. Biomaterials 28:2655-2666. (Pubitemid 46367213)
51. Sou, K., Klipper, R., Goins, B., Tsuchida, E., Phillips, W. T. (2005). Circulation kinetics and organ distribution of Hb-vesicles developed as a red blood cell substitute. J Pharmacol Exp Ter 312:702-709. (Pubitemid 40189569)
52. Spahn, D. R., Kocian, R. (2003). Te place of artifcial oxygen carriers in reducing allogeneic blood transfusions and augmenting tissue oxygenation. Can J Anaesth 50:S41-S47 (Pubitemid 37038498)
53. Stowell, C. P. (2005). What happened to blood substitutes? Transfus Clin Biol 12:374-379. (Pubitemid 41802973)
54. Taguchi, K., Iwao, Y., Watanabe, H., Kadowaki, D., Sakai, H., Kobayashi, K., et al. (2011a). Repeated injection of high doses of hemoglobin encapsulated liposomes (hemoglobin-vesicles) induces accelerated blood clearance in a hemorrhagic shock rat model. Drug Metab Dispos 39:484-489.
55. Taguchi, K., Maruyama, T., Iwao, Y., Sakai, H., Kobayashi, K., Horinouchi, H., et al. (2009a). Pharmacokinetics of single and repeated injection of hemoglobin-vesicles in hemorrhagic shock rat model. J Contr Rel 136:232-239.
56. Taguchi, K., Miyasato, M., Ujihira, H., Watanabe, H., Kadowaki, D., Sakai, H., et al. (2010). Hepatically-metabolized and-excreted artifcial oxygen carrier, hemoglobin-vesicles, can be safely used under conditions of hepatic impairment. Toxicol Appl Pharmacol 248:234-241.
57. Taguchi, K., Miyasato, M., Watanabe, H., Sakai, H., Tsuchida, E., Horinouchi, H., et al. (2011b). Alteration in the pharmacokinetics of hemoglobin-vesicles in a rat model of chronic liver cirrhosis is associated with Kupfer cell phagocyte activity. J Pharm Sci 100:775-783.
58. Taguchi, K., Urata, Y., Anraku, M., Maruyama, T., Watanabe, H., Sakai, H., et al. (2009b). Pharmacokinetic study of enclosed hemoglobin and outer lipid component after the administration of hemoglobin vesicles as an artifcial oxygen carrier. Drug Metab Dispos 37:1456-1463.
59. Taguchi, K., Urata, Y., Anraku, M., Watanabe, H., Kadowaki, D., Sakai, H., et al. (2009c). Hemoglobin vesicles, polyethylene glycol (PEG) ylated liposomes developed as a red blood cell substitute, do not induce the accelerated blood clearance phenomenon in mice. Drug Metab Dispos 37:2197-2203.
60. Takaori, M. (2005). Approach to clinical trial considering medical ethics and efcacy for HbV, liposome encapsulated hemoglobin vesicle. Artif Cells Blood Substit Immobil Biotechnol 33:65-73. (Pubitemid 40315179)
61. Terajima, K., Tsueshita, T., Sakamoto, A., Ogawa, R. (2006). Fluid resuscitation with hemoglobin vesicles in a rabbit model of acute hemorrhagic shock. Shock 25:184-189.
62. Turck, D., Schwarz, A., Hofer, D., Narjes, H. H., Nehmiz, G., Heinzel, G. (1996). Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. Eur J Clin Pharmacol 51:309-313.
63. Walsh, T. J., Yeldandi, V. , McEvoy, M., Gonzalez, C., Chanock, S., Freifeld, A., et al. (1998). Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 42:2391-2398. (Pubitemid 28420384)
64. Wang, X., Ishida, T., Kiwada, H. (2007). Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Contr Rel 119:236-244. (Pubitemid 46759557)
65. Yamamoto, M., Izumi, Y., Horinouchi, H., Teramura, Y., Sakai, H., Kohno, M., et al. (2009). Systemic administration of hemoglobin vesicle elevates tumor tissue oxygen tension and modifes tumor response to irradiation. J Surg Res 151:48-54.
66. Yamazaki, M., Aeba, R., Yozu, R., Kobayashi, K. (2006). Use of hemoglobin vesicles during cardiopulmonary bypass priming prevents neurocognitive decline in rats. Circulation 114:I220-I225 (Pubitemid 44297154)
67. Zweifach, B. W., Benacerraf, B. (1958). Efect of hemorrhagic shock on the phagocytic function of Kupfer cells. Circ Res 6:83-87.